Rheumatology Vol. III
Four topics, 30 cases — choose one below to browse its cases.
Fibromyalgia pharmacotherapy selection among FDA-approved and off-label agents, CRPS treatment under contested and investigational evidence, myofascial and regional pain-syndrome injection choices, and treatment decisions under comorbidity, deadline, and evidence-status constraints
NSAID selection under cardiovascular and GI risk, corticosteroid and hyaluronic acid injection decisions, pain-control bridging under renal impairment, and treatment choices at the edge of what platelet-rich plasma, glucosamine/chondroitin, and conservative management evidence actually supports
Immunosuppression restart timing after native-joint septic arthritis, post-infectious inflammatory arthritis management (Lyme, chikungunya, parvovirus B19), and antibiotic and biologic selection under infectious-resistance and comorbidity constraints
Steroid-sparing agent selection in joint/muscle-dominant sarcoidosis, regimen choice to halt AA amyloidosis in longstanding RA, and treatment decisions at genuine points of diagnostic and evidentiary uncertainty in erythema nodosum, hemochromatosis arthropathy, and statin myalgia